AACR 2025

April 02-30, 2025
Chicago, IL

American Association for Cancer Research

Explore more Oncology congress materials

Results(3)

Oncology

EmpowHER-303: A Phase 3 Study of Zanidatamab vs Trastuzumab With Physician’s Choice of Chemotherapy in Patients With HER2+ Metastatic Breast Cancer Whose Disease Progressed on Trastuzumab Deruxtecan

Author(s): Sara M. Tolaney, Javier Cortes, Erika Hamilton et al.

HERIZON-BTC-302: A Phase 3 Trial of Zanidatamab With Standard-of-Care Therapy vs SOC Alone For First-Line Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced/Metastatic Biliary Tract Cancer

Author(s): James J. Harding, Teresa Macarulla, Xiaotian Wu et al.

Real-World Second-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Overexpressing Biliary Tract Cancer

Author(s): Richard Kim, Xiaozhou Fan, Javier Sabater et al.

Disclaimer

This AI model is continuing to learn and its responses are based on learned data patterns. It should not replace professional judgment. Please verify the information before use, and feedback is welcome to improve its accuracy.

Please do not include personal or confidential information in your searches. For information on how to report an adverse event or product complaint for a Jazz product, please visit: https://www.jazzpharma.com/medicines/drug-safety/.